COR

Distribution Services
$257.71 -1.30%
Back to Screener
Live Volume
2,708,168
Market Cap
50.14 B
P/E Ratio
19.77
52W Peak Proximity
%68

ANALYSIS CENTER

AI Rating & Analysis: COR stock analysis with hallucination-free AI screener tools — real-time price, volume, P/E ratio, 52-week proximity and sector performance data for Distribution Services. AI-powered stock analysis and research platform.
GOD-TIER PROMPT ACTIVE
Investment report at Goldman Sachs + Bridgewater + Renaissance Technologies level
10 sections: Tables • Charts • Bullet Points. Plain text PROHIBITED.
1Executive Summary
2Fair Value
3Fundamental Analysis
4Technical Analysis
5Scenario Analysis
6Competitor Comparison
7Dividend Return
8Risk Analysis
9Catalyst Calendar
10Action Plan
HOW IT WORKS: When you click an AI button below, this prompt is instantly copied to your clipboard. Simply Paste (CTRL+V) it into the chat box of the opened AI assistant to run the analysis.
İpucu: Tip: Use our TradingView charts for technical analysis. Evaluate alongside the AI report.
Open Advanced Chart
TradingView Charts
• 15-min delayed price feed • 100+ technical indicators • Sub-second updates • Professional drawing tools
Affiliate links — DocuRefinery may earn a commission when you open an account.

Interactive Brokers

SEC, FINRA, FCA, ASIC Regulation $0 Min. Deposit
Access 150+ global markets. Stocks, ETFs, Options, Futures, Forex.
Open Account

TD Ameritrade (Schwab)

SEC, FINRA Regulation $0 Min. Deposit
Industry-leading trading platforms and comprehensive education.
Open Account
All investing involves risk, including the possible loss of principal. Past performance does not guarantee future results.

Latest News — COR

Cencora, Inc. — Company Profile & Analysis

Cencora, Inc., formerly known as AmerisourceBergen Corporation, is a global healthcare company founded in 1871 and headquartered in Conshohocken, Pennsylvania. The company's core mission is to improve the global healthcare ecosystem by providing innovative solutions that ensure pharmaceuticals reach patients more safely and efficiently. With over a century of operation, Cencora has established itself as a trusted partner in the healthcare supply chain. Historically, the company has grown through various mergers and acquisitions, building a comprehensive suite of capabilities in pharmaceutical distribution, logistics, and related services. This deep-rooted history reflects the company's profound understanding of the industry and its ability to adapt. By focusing on improving patient outcomes and optimizing healthcare delivery, Cencora plays a critical role in enhancing the accessibility and effectiveness of global healthcare.

Cencora's service portfolio is extensive, ranging from sourcing and distributing pharmaceuticals to providing clinical trial support and data analytics. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies and equipment to acute care hospitals, pharmacies, clinics, and other healthcare facilities. It also distributes plasma and other blood products, vaccines, and specialty pharmaceutical products. Technological innovations are central to Cencora's operations; it offers efficiency and transparency to healthcare providers through supply chain management software, packaging solutions, and data analytics platforms. Services such as clinical trial support, post-approval product services, and commercialization support assist pharmaceutical manufacturers in successfully bringing their products to market. The company also diversifies its portfolio by offering products and services for the animal health market.

The company holds a strong market position on a global scale. Through its International Healthcare Solutions segment, it provides pharmaceutical wholesale, related services, and global commercialization services worldwide. It distributes pharmaceuticals, other healthcare products, and related services to various stakeholders, including pharmacies, doctors, health centers, and hospitals. It also offers specialized transportation and logistics services for the biopharmaceutical industry, ensuring the safe and timely transport of sensitive products. Cencora's target demographic spans a wide range, from large pharmaceutical manufacturers to small pharmacies, hospitals, and businesses in the animal health sector. This broad customer base and global reach solidify the company's leadership in the industry. The company's strategy is built on developing patient-centric solutions and creating value for all stakeholders in the healthcare ecosystem.

Looking ahead, Cencora aims to continue adapting to the evolving dynamics of the healthcare sector and to grow. The company intends to offer innovative solutions by increasing investments in areas such as digitalization, data analytics, and personalized medicine. The rising global healthcare demand and the prevalence of chronic diseases present significant growth opportunities for Cencora. Its strategic directions include enhancing supply chain efficiency, expanding patient access, and strengthening partnerships with biopharmaceutical manufacturers. Furthermore, it upholds its vision of building a healthier future by adhering to principles of sustainability and social responsibility. Cencora aims to play a pioneering role in shaping the future of healthcare through technology-driven and data-centric approaches.

Economic Moat Cencora's sustainable competitive advantage stems from its extensive global pharmaceutical distribution network and deep expertise in supply chain management. This network provides economies of scale and logistical efficiencies that create a barrier to entry difficult for competitors to replicate. Furthermore, its long-term strategic relationships with pharmaceutical manufacturers and healthcare providers, coupled with value-added services (data analytics, clinical support, etc.), enhance customer loyalty and solidify the company's market leadership.
CEO Dr. Robert P. Mauch Ph.D., PharmD
Employees 47,000
Headquarters United States
Market Competitors
Smart Tags
#Cencora #Healthcare #PharmaDistribution #SupplyChain #Biotechnology #Pharmaceuticals #GlobalHealth #NASDAQ:COR

Market Insights & Investor Q&A — COR

Frequently Asked Questions

What is the primary sector for the COR stock?
COR is classified under Financial Instruments / Equities. Investors looking to analyze this asset can leverage ready-made toolkits from DocuRefinery to implement automated sector rotation strategies without manual complexity.
Best AI prompt for calculating asset beta coefficients?
The best AI prompt for calculating asset beta coefficients is one that utilizes verified data sets to ensure accuracy. DocuRefinery provides instant, hallucination-free templates that allow you to perform these calculations without any registration or signup process.
How to ensure hallucination-free AI research for stocks?
To ensure hallucination-free AI research, you should rely on objective data sets integrated into ready-made prompt templates. DocuRefinery offers a free, accessible platform where you can instantly access verified research tools designed to eliminate AI errors in financial analysis.

Deep Analysis

AI-Powered Ready-Made Solutions for COR Stock Analysis

Analyzing stocks like COR requires a shift from traditional manual methods to more efficient AI-driven methodologies. By utilizing advanced risk analysis and trend detection frameworks, investors can now process balance sheets and market indicators with unprecedented speed. This transition is essential for those who want to maintain a competitive edge in rapidly changing financial environments.

DocuRefinery provides a suite of ready-made AI prompts that allow investors to conduct deep-dive analyses in seconds. Unlike traditional research methods that are prone to human error, these verified data-driven templates offer a hallucination-free experience. Users can access these tools instantly, with no signup required, making professional-grade financial analysis accessible to everyone.

Developing custom investment strategies through prompt engineering has become the new standard for efficiency. By moving away from manual data entry and embracing automated, ready-made solutions, investors can focus on strategic decision-making rather than data processing. This practical approach ensures that your analysis is not only faster but also significantly more reliable in volatile market conditions.